Difference between revisions of "Amatuximab (MORAb-009)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m |
||
| Line 1: | Line 1: | ||
=Mechanism of action= | =Mechanism of action= | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=489384 NCI Drug Dictionary]: A humanized IgG1 monoclonal antibody directed against human mesothelin with potential antineoplastic activity. Amatuximab binds to mesothelin, triggering an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing tumor cells, which may result in tumor cell lysis. Mesothelin, a 40kDa cell surface glycoprotein, is overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinomas. | |
=Preliminary data= | =Preliminary data= | ||
| Line 7: | Line 7: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Intravenous medications]] |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
Revision as of 18:29, 29 October 2017
Mechanism of action
From the NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against human mesothelin with potential antineoplastic activity. Amatuximab binds to mesothelin, triggering an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing tumor cells, which may result in tumor cell lysis. Mesothelin, a 40kDa cell surface glycoprotein, is overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinomas.
Preliminary data
Mesothelioma
- Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article PubMed